Our Team

Jaswinder Khera-US Managing Director

Jaswinder brings over 30 years of experience in the Pharmaceutical Industry in senior sales and marketing positions with Sanofi, MSD and Astra. He also held senior management positions in operations and business development during his 10 years with Quintiles the world’s largest CRO. He oversees the growth and strategy of the business in the Americas.

Jaswant Khera – EU Managing Director

Following award winning sales and management experience with Pfizer, where he led a team that marketed the global blockbuster Lipitor, Jaswant went on to launch WE Pharma  now called WEP Clinical. He brings with him 18 years of commercial, strategic, operational and marketing experience as well as a deep understanding of international markets and commercialization of drugs. Currently serving as Managing Director EU, he is responsible for the growth and strategy of the business.

Matt Comstock – Business Development Director

Matt is responsible for developing new customer accounts as well as growing relationships with existing customers.  Matt has been in the Pharmaceutical industry for over 16 years, and has experience in research, strategic account management, sales and relationship development.  Prior to working with WEP Clinical, he spent nearly 15 years at Quintiles in Data Management and Finance.

Amandip Sidhu – Expanded Access Programs Director

Amandip has harnessed a clinical background in pharmacy to develop industry-leading solutions. Previously, as part of an international PLC healthcare company, he was responsible for creating and implementing the company’s EAP strategy. This ‘out of the box’ approach in providing patient access solutions to medicines and fulfilling patients unmet needs is a continuing passion of Amandip.

Carlos Marafusta – Latin Region Business Development

Carlos joined WEP Clinical in 2013 as the Latin Area Business Manager from Bristol Myers Squibb and as a native Portuguese speaker he is well placed to serve the Latin area. He has an in depth knowledge of the unlicensed specialty care market and 20 years’ experience in the industry across a range of disciplines, including commercial, strategic, operational and sales and marketing roles for companies such as Pfizer and Astra Zeneca.

Megan Batchelor – Operations & Quality Director

Megan joined WEP Clinical in 2016 as the Operations & Quality Manager.  She is responsible for helping to grow and develop quality systems and processes while focusing on continuous improvement of current operational processes.  Megan has been in the pharmaceutical industry for over 8 years and has extensive experience in facility startup, quality operations, engineering, and project management.  Prior to working at WEP Clinical, Megan spent her time working at Novartis Vaccines & Diagnostics.

Richard Crawley – Regulatory Affairs 

Richard has over forty years’ experience in the pharmaceutical industry in preclinical Drug Metabolism and Pharmacokinetics, global Regulatory Affair and Drug Development Planning and Management. He has served in senior regulatory positions with the Welcome Foundation (UK), Burroughs Welcome (USA) and Pozen Inc. (USA) covering Phase 1 through Phase 4 development activities and has extensive experience interacting with worldwide regulatory authorities. During his career, he has been involved in more than 20 MAA/NDA submissions for NCEs and over 70 clinical trial applications globally for drug, biologics and devices.

Chris Barnett – Regulatory Affairs 

Chris has had an extensive career in the development, manufacturing and supply chain management in the pharmaceutical and biopharmaceutical industries. Experience in the principles of International Quality Assurance, Project and Line Management gained in various tenures at the Wellcome Foundation Limited, Glaxo Wellcome and Glaxo SmithKline led Chris to his certification as an EU Qualified Person (QP) with particular expertise in clinical trial materials. His forty years’ experience enables him to provide expert knowledge of the principles and regulation of Good Manufacturing Practice (GMP), Good Distribution Practice (GDP) and Quality Assurance of both marketed products and those still under development, with a strategic and commercial angle.